Barrs Pharmaceuticals Secures R92m Hetero Investment

Barrs Pharmaceuticals has exited business rescue after agreeing to sell a controlling stake to Hetero. The deal signals a reset for a local manufacturer that has faced both operational disruption and regulatory pressure. Business rescue consultant Karl Gribnitz announced that the Indian generics group’s South African subsidiary will acquire 78% of Barrs for R92m. The group intends this investment to…

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in